GSK throws €142m behind innovative vaccine developer CureVac
British drug giant GlaxoSmithKline has backed a “cutting edge” player in the race to develop a vaccine for coronavirus.
GSK said it was putting £130m (€142m) into CureVac for 10% of the business and would make an upfront payment of £104m (€114m).
Read
Listen
Watch
Play
CONNECT WITH US TODAY
Be the first to know the latest news and updates
The Business Hub
Newsletter
News and analysis on business, money and jobs from Munster and beyond by our expert team of business writers.
Business
Push Notifications
By clicking on sign up you will be the first to know about a selection of business content on this browser. Please note if you are unable to sign up via your mobile web browser, download and sign up for mobile push notifications via our FREE news app.
Sign UpThe Business Hub
Newsletter
News and analysis on business, money and jobs from Munster and beyond by our expert team of business writers.
Lunchtime News
Newsletter
Get a lunch briefing straight to your inbox at noon daily. Also be the first to know with our occasional Breaking News emails.
Love your Irish Examiner newspaper? We'll deliver it straight to your door for free.
Revoiced
Newsletter
Had a busy week? Sign up for some of the best reads from the week gone by. Selected just for you.
Most Read
Tuesday, June 23, 2026 - 10:00 PM
Tuesday, June 23, 2026 - 2:00 PM
Tuesday, June 23, 2026 - 2:00 PM
